可选产品分析
经您允许,我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
Quest Diagnostics Incorporated's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $21.1B | |
|---|---|---|
| P/E (forward) | 16.3x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $10.79B | $9.88B | $9.25B | $9.87B | $11.04B | +0.6% |
| Gross profit | $4.21B | $3.43B | $3.05B | $3.24B | $3.67B | -3.4% |
| Operating income | $2.75B | $1.38B | $1.29B | $1.40B | $1.60B | -12.7% |
| Net income | $2.00B | $946.0M | $854.0M | $871.0M | $992.0M | -16.0% |
| EPS (diluted) | $15.55 | $7.97 | $7.49 | $7.69 | $8.75 | -13.4% |
| EBITDA | $3.16B | $1.82B | $1.73B | $1.89B | $2.17B | -9.0% |
| R&D | — | — | — | — | — | — |
| SG&A | $1.73B | $1.87B | $1.64B | $1.77B | $1.97B | +3.3% |
Recent company headlines from major financial publishers.
Accretive hospital lab system acquisitions, expansion in advanced and esoteric testing (e.g., Alzheimer's, cancer), and continued realization of cost synergies lead to margin expansion and faster-than-expected organic growth.
Quest Diagnostics is a mature, highly cash-generative leader in the US diagnostic testing market. Its robust national network provides durable scale advantages, supporting consistent free cash flow generation and a reliable, growing dividend.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 4.3% | $308 | $375 | $396 | $396 | $396 |
| 5.3% | $226 | $261 | $308 | $375 | $396 |
| 6.3% | $179 | $200 | $226 | $261 | $308 |
| 7.3% | $148 | $162 | $179 | $200 | $226 |
| 8.3% | $126 | $136 | $148 | $162 | $179 |
Upcoming earnings date and setup when available.
每月发布的研究版本所给出的评级。评级比较分析日的价格与公允价值,并不记录判断是否正确。
| 年份 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |